Compare
Madrigal Pharmaceuticals, Inc. vs ANI Pharmaceuticals Inc vs Prestige Consumer Healthcare Inc. vs Corcept Therapeutics Inc
| Latest fiscal year | Madrigal Pharmaceuticals, Inc. MDGL | ANI Pharmaceuticals Inc ANIP | Prestige Consumer Healthcare Inc. PBH | Corcept Therapeutics Inc CORT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $958.40M | $883.37M | $1.09B | $761.41M |
| Revenue growth (YoY) | +432.1% | +43.8% | -4.3% | +12.8% |
| Gross margin | n/a | n/a | 54.7% | n/a |
| Operating margin | -31.3% | 12.6% | 28.4% | 5.9% |
| Net margin | -30.1% | 8.9% | 17.5% | 13.1% |
| Net income | -$288.28M | $78.34M | $190.30M | $99.65M |
| EPS (Diluted) | -$12.85 | $3.32 | $3.91 | $0.82 |
| Operating cash flow | -$189.55M | $185.22M | $257.63M | $142.00M |
| Free cash flow | -$190.02M | $171.39M | $246.45M | $141.78M |
| Cash & equivalents | $198.69M | $285.58M | $63.87M | $120.50M |
| Total assets | $1.26B | $1.44B | $3.49B | $836.65M |
| Total liabilities | $656.90M | $899.65M | $1.61B | $188.85M |
| Shareholders' equity | $602.69M | $540.72M | $1.89B | $647.80M |
| Return on year-end equity | -47.8% | 14.5% | 10.1% | 15.4% |
| Shares outstanding | 22.84M | 22.49M | n/a | 105.97M |
Revenue, most recent five fiscal years
| Fiscal year | Madrigal Pharmaceuticals, Inc. | ANI Pharmaceuticals Inc | Prestige Consumer Healthcare Inc. | Corcept Therapeutics Inc |
|---|---|---|---|---|
| Latest | $958.40M Ended 2025-12-31 | $883.37M Ended 2025-12-31 | $1.09B Ended 2026-03-31 | $761.41M Ended 2025-12-31 |
| 1 year earlier | $180.13M Ended 2024-12-31 | $614.38M Ended 2024-12-31 | $1.14B Ended 2025-03-31 | $675.04M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $486.82M Ended 2023-12-31 | $1.13B Ended 2024-03-31 | $482.38M Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $316.38M Ended 2022-12-31 | $1.13B Ended 2023-03-31 | $401.86M Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $216.14M Ended 2021-12-31 | $1.09B Ended 2022-03-31 | $365.98M Ended 2021-12-31 |